H.C. Wainwright adjusted its outlook on Zentalis Pharmaceuticals (NASDAQ:ZNTL), reducing the price target to $10.00 from the previous $20.00, yet reaffirming a Buy rating on the company's shares. The ...
Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price target decreased by UBS Group from $5.00 to $2.20 in a research report released on Tuesday,Benzinga reports. UBS Group currently has ...